BRENDA - Enzyme Database show
show all sequences of 3.4.22.26

Cancer procoagulant

Gordon, S.G.; Methods Enzymol. 244, 568-583 (1994)

Data extracted from this reference:

Activating Compound
Activating Compound
Commentary
Organism
Structure
additional information
no activation with 0.005 mM cysteine and 4 mM KCN
Homo sapiens
additional information
no activation with 0.005 mM cysteine and 4 mM KCN
Rattus norvegicus
General Stability
General Stability
Organism
Polyethylene glycol preparation yields stable enzyme
Homo sapiens
Polyethylene glycol preparation yields stable enzyme
Rattus norvegicus
Prefers lipid environment, phospholipids stabilize
Homo sapiens
Prefers lipid environment, phospholipids stabilize
Rattus norvegicus
Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum
Homo sapiens
Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum
Rattus norvegicus
Inhibitors
Inhibitors
Commentary
Organism
Structure
alpha1-Aantichymotrypsin
weak
Homo sapiens
alpha1-Aantichymotrypsin
weak
Rattus norvegicus
alpha2-Macroglobulin
weak
Homo sapiens
alpha2-Macroglobulin
weak
Rattus norvegicus
antipain
enhanced in reduced environment
Homo sapiens
antipain
enhanced in reduced environment
Rattus norvegicus
diisopropylfluorophosphate
strong
Homo sapiens
diisopropylfluorophosphate
strong
Rattus norvegicus
HgCl2
strong, less effective in reduced environment
Homo sapiens
HgCl2
strong, less effective in reduced environment
Rattus norvegicus
iodoacetamide
strong, still enhanced in reduced environment
Homo sapiens
iodoacetamide
strong, still enhanced in reduced environment
Rattus norvegicus
leupeptin
enhanced in reduced environment
Homo sapiens
leupeptin
enhanced in reduced environment
Rattus norvegicus
additional information
cystatin, alpha1-antiprotease, antithrombin III
Homo sapiens
additional information
cystatin, alpha1-antiprotease, antithrombin III
Rattus norvegicus
Peptidyl chloromethanes
-
Homo sapiens
Peptidyl chloromethanes
-
Rattus norvegicus
Peptidyl diazomethanes
-
Homo sapiens
Peptidyl diazomethanes
-
Rattus norvegicus
Peptidyl dimethylsulfonium salts
-
Homo sapiens
Peptidyl dimethylsulfonium salts
-
Rattus norvegicus
phenylmethylsulfonyl fluoride
-
Homo sapiens
phenylmethylsulfonyl fluoride
-
Rattus norvegicus
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane
enhanced in reduced environment
Homo sapiens
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane
enhanced in reduced environment
Rattus norvegicus
Metals/Ions
Metals/Ions
Commentary
Organism
Structure
Ca2+
requirement, 7 mM
Homo sapiens
Ca2+
requirement, 7 mM
Rattus norvegicus
Mg2+
10 mM; requirement, can replace Ca2+
Homo sapiens
Mg2+
10 mM; requirement, can replace Ca2+
Rattus norvegicus
Mn2+
but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+
Homo sapiens
Mn2+
but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+
Rattus norvegicus
additional information
binding cancer procoagulant to a surface changes its divalent ion requirements
Homo sapiens
additional information
binding cancer procoagulant to a surface changes its divalent ion requirements
Rattus norvegicus
Molecular Weight [Da]
Molecular Weight [Da]
Molecular Weight Maximum [Da]
Commentary
Organism
additional information
-
amino acid composition of rabbit V2 and human amnion-chorion enzymes
Homo sapiens
additional information
-
-
Rattus norvegicus
Organism
Organism
Primary Accession No. (UniProt)
Commentary
Textmining
Homo sapiens
-
-
-
Rattus norvegicus
-
-
-
Oxidation Stability
Oxidation Stability
Organism
sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize
Homo sapiens
sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize
Rattus norvegicus
Posttranslational Modification
Posttranslational Modification
Commentary
Organism
no glycoprotein
no glycoprotein
Homo sapiens
no glycoprotein
no glycoprotein
Rattus norvegicus
Source Tissue
Source Tissue
Commentary
Organism
Textmining
amelanotic melanoma cell
-
Rattus norvegicus
-
carcinoma cell
-
Rattus norvegicus
-
Lewis lung carcinoma cell
-
Rattus norvegicus
-
additional information
unique in fetal tissues, not in normally differentiated tissues; unique in tumor
Homo sapiens
-
additional information
unique in fetal tissues, not in normally differentiated tissues; unique in tumor
Rattus norvegicus
-
placenta
amnion-chorion tissue
Homo sapiens
-
Walker carcinoma 256 cell
-
Rattus norvegicus
-
Substrates and Products (Substrate)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
Factor X + H2O
primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19
30160
Homo sapiens
Factor Xa + ?
-
30160
Homo sapiens
-
Factor X + H2O
primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19
30160
Rattus norvegicus
Factor Xa + ?
-
30160
Rattus norvegicus
-
Temperature Optimum [°C]
Temperature Optimum [°C]
Temperature Optimum Maximum [°C]
Commentary
Organism
37
-
assay at
Homo sapiens
37
-
assay at
Rattus norvegicus
Activating Compound (protein specific)
Activating Compound
Commentary
Organism
Structure
additional information
no activation with 0.005 mM cysteine and 4 mM KCN
Homo sapiens
additional information
no activation with 0.005 mM cysteine and 4 mM KCN
Rattus norvegicus
General Stability (protein specific)
General Stability
Organism
Polyethylene glycol preparation yields stable enzyme
Homo sapiens
Polyethylene glycol preparation yields stable enzyme
Rattus norvegicus
Prefers lipid environment, phospholipids stabilize
Homo sapiens
Prefers lipid environment, phospholipids stabilize
Rattus norvegicus
Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum
Homo sapiens
Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum
Rattus norvegicus
Inhibitors (protein specific)
Inhibitors
Commentary
Organism
Structure
alpha1-Aantichymotrypsin
weak
Homo sapiens
alpha1-Aantichymotrypsin
weak
Rattus norvegicus
alpha2-Macroglobulin
weak
Homo sapiens
alpha2-Macroglobulin
weak
Rattus norvegicus
antipain
enhanced in reduced environment
Homo sapiens
antipain
enhanced in reduced environment
Rattus norvegicus
diisopropylfluorophosphate
strong
Homo sapiens
diisopropylfluorophosphate
strong
Rattus norvegicus
HgCl2
strong, less effective in reduced environment
Homo sapiens
HgCl2
strong, less effective in reduced environment
Rattus norvegicus
iodoacetamide
strong, still enhanced in reduced environment
Homo sapiens
iodoacetamide
strong, still enhanced in reduced environment
Rattus norvegicus
leupeptin
enhanced in reduced environment
Homo sapiens
leupeptin
enhanced in reduced environment
Rattus norvegicus
additional information
cystatin, alpha1-antiprotease, antithrombin III
Homo sapiens
additional information
cystatin, alpha1-antiprotease, antithrombin III
Rattus norvegicus
Peptidyl chloromethanes
-
Homo sapiens
Peptidyl chloromethanes
-
Rattus norvegicus
Peptidyl diazomethanes
-
Homo sapiens
Peptidyl diazomethanes
-
Rattus norvegicus
Peptidyl dimethylsulfonium salts
-
Homo sapiens
Peptidyl dimethylsulfonium salts
-
Rattus norvegicus
phenylmethylsulfonyl fluoride
-
Homo sapiens
phenylmethylsulfonyl fluoride
-
Rattus norvegicus
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane
enhanced in reduced environment
Homo sapiens
trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane
enhanced in reduced environment
Rattus norvegicus
Metals/Ions (protein specific)
Metals/Ions
Commentary
Organism
Structure
Ca2+
requirement, 7 mM
Homo sapiens
Ca2+
requirement, 7 mM
Rattus norvegicus
Mg2+
10 mM; requirement, can replace Ca2+
Homo sapiens
Mg2+
10 mM; requirement, can replace Ca2+
Rattus norvegicus
Mn2+
but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+
Homo sapiens
Mn2+
but different binding site than Ca2+ (or Mg2+), 0.02 mM; requirement, can replace Ca2+
Rattus norvegicus
additional information
binding cancer procoagulant to a surface changes its divalent ion requirements
Homo sapiens
additional information
binding cancer procoagulant to a surface changes its divalent ion requirements
Rattus norvegicus
Molecular Weight [Da] (protein specific)
Molecular Weight [Da]
Molecular Weight Maximum [Da]
Commentary
Organism
additional information
-
amino acid composition of rabbit V2 and human amnion-chorion enzymes
Homo sapiens
additional information
-
-
Rattus norvegicus
Oxidation Stability (protein specific)
Oxidation Stability
Organism
sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize
Homo sapiens
sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize
Rattus norvegicus
Posttranslational Modification (protein specific)
Posttranslational Modification
Commentary
Organism
no glycoprotein
no glycoprotein
Homo sapiens
no glycoprotein
no glycoprotein
Rattus norvegicus
Source Tissue (protein specific)
Source Tissue
Commentary
Organism
Textmining
amelanotic melanoma cell
-
Rattus norvegicus
-
carcinoma cell
-
Rattus norvegicus
-
Lewis lung carcinoma cell
-
Rattus norvegicus
-
additional information
unique in fetal tissues, not in normally differentiated tissues; unique in tumor
Homo sapiens
-
additional information
unique in fetal tissues, not in normally differentiated tissues; unique in tumor
Rattus norvegicus
-
placenta
amnion-chorion tissue
Homo sapiens
-
Walker carcinoma 256 cell
-
Rattus norvegicus
-
Substrates and Products (Substrate) (protein specific)
Substrates
Commentary Substrates
Literature (Substrates)
Organism
Products
Commentary (Products)
Literature (Products)
Organism (Products)
Reversibility
Factor X + H2O
primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19
30160
Homo sapiens
Factor Xa + ?
-
30160
Homo sapiens
-
Factor X + H2O
primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19
30160
Rattus norvegicus
Factor Xa + ?
-
30160
Rattus norvegicus
-
Temperature Optimum [°C] (protein specific)
Temperature Optimum [°C]
Temperature Optimum Maximum [°C]
Commentary
Organism
37
-
assay at
Homo sapiens
37
-
assay at
Rattus norvegicus
Other publictions for EC 3.4.22.26
No.
1st author
Pub Med
title
organims
journal
volume
pages
year
Activating Compound
Application
Cloned(Commentary)
Crystallization (Commentary)
Engineering
General Stability
Inhibitors
KM Value [mM]
Localization
Metals/Ions
Molecular Weight [Da]
Natural Substrates/ Products (Substrates)
Organic Solvent Stability
Organism
Oxidation Stability
Posttranslational Modification
Purification (Commentary)
Reaction
Renatured (Commentary)
Source Tissue
Specific Activity [micromol/min/mg]
Storage Stability
Substrates and Products (Substrate)
Subunits
Temperature Optimum [°C]
Temperature Range [°C]
Temperature Stability [°C]
Turnover Number [1/s]
pH Optimum
pH Range
pH Stability
Cofactor
Ki Value [mM]
pI Value
IC50 Value
Activating Compound (protein specific)
Application (protein specific)
Cloned(Commentary) (protein specific)
Cofactor (protein specific)
Crystallization (Commentary) (protein specific)
Engineering (protein specific)
General Stability (protein specific)
IC50 Value (protein specific)
Inhibitors (protein specific)
Ki Value [mM] (protein specific)
KM Value [mM] (protein specific)
Localization (protein specific)
Metals/Ions (protein specific)
Molecular Weight [Da] (protein specific)
Natural Substrates/ Products (Substrates) (protein specific)
Organic Solvent Stability (protein specific)
Oxidation Stability (protein specific)
Posttranslational Modification (protein specific)
Purification (Commentary) (protein specific)
Renatured (Commentary) (protein specific)
Source Tissue (protein specific)
Specific Activity [micromol/min/mg] (protein specific)
Storage Stability (protein specific)
Substrates and Products (Substrate) (protein specific)
Subunits (protein specific)
Temperature Optimum [°C] (protein specific)
Temperature Range [°C] (protein specific)
Temperature Stability [°C] (protein specific)
Turnover Number [1/s] (protein specific)
pH Optimum (protein specific)
pH Range (protein specific)
pH Stability (protein specific)
pI Value (protein specific)
Expression
General Information
General Information (protein specific)
Expression (protein specific)
KCat/KM [mM/s]
KCat/KM [mM/s] (protein specific)
733446
Kee
The effect of cancer procoagul ...
Homo sapiens
Biol. Chem.
393
113-121
2012
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
1
-
-
-
701292
Musallam
Incidence and prophylaxis of v ...
Homo sapiens
Thromb. Res.
123
679-686
2009
-
-
-
-
-
-
-
-
-
-
-
1
-
2
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
710603
Kaplinska
Cancer procoagulant (CP) analy ...
Homo sapiens
Thromb. Res.
124
364-367
2009
-
-
-
-
-
-
2
-
1
2
-
-
-
2
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
1
2
-
-
-
-
-
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
697471
Kamocka
Rat prostate tumors express ca ...
Rattus norvegicus
Comp. Med.
58
282-286
2008
-
-
-
-
-
-
2
-
-
-
-
2
-
3
-
-
1
-
-
2
11
-
3
-
-
-
-
-
1
-
-
-
-
-
1
-
-
-
-
-
-
-
1
2
-
-
-
-
-
2
-
-
-
1
-
2
11
-
3
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
679297
Kamocka
Effect of immunisation with ca ...
Homo sapiens
Clin. Exp. Med.
6
119-123
2006
-
1
-
-
-
-
1
-
-
1
-
-
-
4
-
-
1
-
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
1
-
-
-
1
-
-
-
-
-
1
-
2
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
679638
Szajda
Analysis of the relationship b ...
Homo sapiens
Eur. J. Gynaecol. Oncol.
27
495-499
2006
1
-
-
-
-
-
-
-
-
-
-
1
-
2
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
3
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
668075
Kazmierczak
Cancer procoagulant in patient ...
Homo sapiens
Blood Coagul. Fibrinolysis
16
543-547
2005
-
-
-
-
-
-
-
-
1
-
-
2
-
2
-
-
-
-
-
4
1
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
4
1
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
668137
Kamocka
Effect of cancer procoagulant ...
Homo sapiens
Cancer Lett.
222
89-94
2005
-
-
-
-
-
-
1
-
-
-
-
2
-
1
-
-
1
-
-
3
-
-
3
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
-
-
-
2
-
-
-
1
-
3
-
-
3
-
1
-
-
-
1
-
-
-
-
-
-
-
-
-
668476
Jozwik
The activity of cancer procoag ...
Homo sapiens
Eur. J. Gynaecol. Oncol.
26
407-410
2005
-
-
-
-
-
-
-
-
1
-
-
2
-
2
-
-
-
-
-
7
1
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
1
-
-
2
-
-
-
-
-
7
1
-
4
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
667302
Raasi
Properties of proteins in canc ...
Homo sapiens
Arch. Biochem. Biophys.
428
131-135
2004
-
-
-
-
-
-
2
-
-
2
-
1
-
1
-
-
1
-
-
1
1
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
2
-
1
-
-
-
1
-
1
1
-
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
651435
Mielicki
Biochemistry of cancer procoag ...
Homo sapiens, Oryctolagus cuniculus
Haemostasis
31 Suppl 1
8-10
2001
8
-
-
-
-
-
24
-
1
2
1
4
-
2
-
2
1
-
-
6
-
-
13
1
-
-
-
-
-
-
-
-
1
1
-
8
-
-
-
-
-
-
-
24
1
-
1
2
1
4
-
-
2
1
-
6
-
-
13
1
-
-
-
-
-
-
-
1
-
-
-
-
-
-
653983
Mielicki
Cancer procoagulant activity s ...
Homo sapiens
Thromb. Res.
87
251-256
1997
-
1
-
-
-
-
2
5
-
-
-
1
-
1
-
-
1
-
-
3
2
-
18
-
-
-
-
5
1
-
-
-
-
-
-
-
1
-
-
-
-
-
-
2
-
5
-
-
-
1
-
-
-
1
-
3
2
-
18
-
-
-
-
5
1
-
-
-
-
-
-
-
-
-
30160
Gordon
Cancer procoagulant ...
Homo sapiens, Rattus norvegicus
Methods Enzymol.
244
568-583
1994
2
-
-
-
-
6
26
-
-
8
2
-
-
2
2
2
-
-
-
7
-
-
2
-
2
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
6
-
26
-
-
-
8
2
-
-
2
2
-
-
7
-
-
2
-
2
-
-
-
-
-
-
-
-
-
-
-
-
-
30161
Mielicki
Effect of divalent ions on the ...
Homo sapiens
Arch. Biochem. Biophys.
314
165-170
1994
-
-
-
-
-
-
3
-
1
4
-
-
-
1
-
-
1
-
-
1
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
3
-
-
1
4
-
-
-
-
-
1
-
1
1
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30159
Moore
The purification and propertie ...
Mus musculus
Biochem. Biophys. Res. Commun.
184
819-824
1992
-
-
-
-
-
-
12
-
1
1
1
1
-
3
-
-
1
-
-
6
-
1
4
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
12
-
-
1
1
1
1
-
-
-
1
-
6
-
1
4
1
1
-
-
-
-
-
-
-
-
-
-
-
-
-
30158
Falanga
Inhibition of cancer procoagul ...
Oryctolagus cuniculus
Thromb. Res.
54
389-398
1989
-
-
-
-
-
-
2
-
-
-
-
-
-
1
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
-
-
-
-
-
-
-
3
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30157
Falanga
Several murine metastasizing t ...
Mus musculus, Oryctolagus cuniculus
Int. J. Cancer
39
774-777
1987
-
-
-
-
-
-
-
-
-
-
-
4
-
4
-
-
-
-
-
8
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
4
-
-
-
-
-
8
-
-
6
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
30156
Falanga
Isolation and characterization ...
Oryctolagus cuniculus
Biochemistry
24
5558-5567
1985
-
-
-
-
-
-
2
-
-
-
2
1
-
2
-
1
1
-
-
3
-
-
2
1
1
-
-
-
1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
2
-
-
-
-
2
1
-
-
1
1
-
3
-
-
2
1
1
-
-
-
1
-
-
-
-
-
-
-
-
-